345 related articles for article (PubMed ID: 29153942)
1. Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.
Lebdai S; Mathieu R; Leger J; Haillot O; Vincendeau S; Rioux-Leclercq N; Fournier G; Perrouin-Verbe MA; Doucet L; Azzouzi AR; Rigaud J; Renaudin K; Charles T; Bruyere F; Fromont G
Urol Oncol; 2018 Feb; 36(2):80.e17-80.e24. PubMed ID: 29153942
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
[TBL] [Abstract][Full Text] [Related]
3. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
4. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
[TBL] [Abstract][Full Text] [Related]
5. Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy.
Bhindi B; Xie WY; Kulkarni GS; Hamilton RJ; Nesbitt M; Finelli A; Zlotta AR; Evans A; van der Kwast TH; Alibhai SM; Trachtenberg J; Fleshner NE
Urology; 2016 Jul; 93():77-85. PubMed ID: 27015944
[TBL] [Abstract][Full Text] [Related]
6. Impact of metabolic syndrome on oncologic outcomes at radical prostatectomy.
Morlacco A; Dal Moro F; Rangel LJ; Carlson RE; Schulte PJ; Jeffrey KR
Urol Oncol; 2018 Dec; 36(12):528.e1-528.e6. PubMed ID: 30446466
[TBL] [Abstract][Full Text] [Related]
7. Low circulating free and bioavailable testosterone levels as predictors of high-grade tumors in patients undergoing radical prostatectomy for localized prostate cancer.
Léon P; Seisen T; Cussenot O; Drouin SJ; Cattarino S; Compérat E; Renard-Penna R; Mozer P; Bitker MO; Rouprêt M
Urol Oncol; 2015 Sep; 33(9):384.e21-7. PubMed ID: 25595576
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Role of Preoperative Serum Lipid Levels in Patients Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer.
Wettstein MS; Saba K; Umbehr MH; Murtola TJ; Fankhauser CD; Adank JP; Hofmann M; Sulser T; Hermanns T; Moch H; Wild P; Poyet C
Prostate; 2017 Apr; 77(5):549-556. PubMed ID: 28093792
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study.
Liu Z; Zhu X; He J; Lu J
BMC Cancer; 2023 Jan; 23(1):50. PubMed ID: 36641426
[TBL] [Abstract][Full Text] [Related]
11. Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.
Takeuchi N; Sakamoto S; Nishiyama A; Horikoshi T; Yamada Y; Iizuka J; Maimaiti M; Imamura Y; Kawamura K; Imamoto T; Komiya A; Ikehara Y; Akakura K; Ichikawa T
Clin Genitourin Cancer; 2018 Aug; 16(4):e817-e829. PubMed ID: 29576444
[TBL] [Abstract][Full Text] [Related]
12. The metabolic syndrome is associated with more aggressive prostate cancer.
Ozbek E; Otunctemur A; Dursun M; Sahin S; Besiroglu H; Koklu I; Erkoc M; Danis E; Bozkurt M
Asian Pac J Cancer Prev; 2014; 15(9):4029-32. PubMed ID: 24935591
[TBL] [Abstract][Full Text] [Related]
13. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
14. Metabolic syndrome increases the risk of upgrading and upstaging in patients with prostate cancer on biopsy: a radical prostatectomy multicenter cohort study.
De Nunzio C; Brassetti A; Simone G; Lombardo R; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):438-445. PubMed ID: 29867154
[TBL] [Abstract][Full Text] [Related]
15. Bioptic intraprostatic chronic inflammation predicts adverse pathology at radical prostatectomy in patients with low-grade prostate cancer.
Sanguedolce F; Falagario UG; Castellan P; Di Nauta M; Silecchia G; Bruno SM; Russo D; Treacy PJ; Tewari AK; Montironi R; Carrieri G; Cormio L
Urol Oncol; 2020 Oct; 38(10):793.e19-793.e25. PubMed ID: 32220548
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
Takeshima Y; Yamada Y; Teshima T; Fujimura T; Kakutani S; Hakozaki Y; Kimura N; Akiyama Y; Sato Y; Kawai T; Yamada D; Kume H
BMC Cancer; 2021 May; 21(1):501. PubMed ID: 33947348
[TBL] [Abstract][Full Text] [Related]
17. A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.
Koie T; Mitsuzuka K; Narita S; Yoneyama T; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C
Scand J Urol; 2015 Apr; 49(2):103-7. PubMed ID: 25165894
[TBL] [Abstract][Full Text] [Related]
18. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
[TBL] [Abstract][Full Text] [Related]
19. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
20. The effect of metabolic syndrome on prostate cancer final pathology.
Caliskan S; Kaba S; Özsoy E; Keleş MO; Koca O; Akyüz M; Karaman MI
J Cancer Res Ther; 2019 Mar; 15(Supplement):S47-S50. PubMed ID: 30900620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
